Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCerity Partners LLC
Latest Disclosed Ownership296,654 shares
Latest Disclosed Value $ 132,467,987
Cerity Partners LLC reports 13.42% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Cerity Partners LLC filed a 13F-HR form disclosing ownership of 296,654 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $132,467,877 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 261,553 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 13.42% during the quarter. The current value of the position is $127,068,774 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 296,654 35,101 13.42 132,468 11.71 0.0930
2026-02-11 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 261,553 2,745 1.06 118,577 16.99 0.1728
2025-10-22 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 258,808 -4,884 -1.85 101,359 -13.66 0.1644
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS Stock 92532F100 263,692 10,768 4.26 117,395 -4.26 0.2093
2025-04-30 2025-03-31 13F VERTEX PHARMACEUTICALS Stock 92532F100 252,924 14,895 6.26 122,622 25.78 0.2484
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS Stock 92532F100 238,029 8,987 3.92 97,492 -8.48 0.2115
2024-11-12 2024-09-30 13F VERTEX PHARMACEUTICALS Stock 92532F100 229,042 29,225 14.63 106,523 13.74 0.2359
2024-08-13 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 199,817 5,085 2.61 93,658 15.06 0.2466
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS Equities 92532F100 194,732 63,837 48.77 81,399 52.83 0.2150
2024-01-26 2023-12-31 13F VERTEX PHARMACEUTICALS Equity 92532F100 130,895 58,974 82.00 53,260 112.96 0.1750
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS Equities 92532F100 71,921 23,232 47.72 25,010 45.96 0.1216
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS Equities 92532F100 48,689 8,958 22.55 17,134 5.32 0.0667
2023-05-11 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 39,731 35,687 882.47 16,270 1,294.09 0.0384
2023-02-15 2022-12-31 13F VERTEX PHARMACEUTICALS Equities 92532F100 4,044 1,267 45.62 1,168 45.15 0.0075
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS Equities 92532F100 2,777 223 8.73 804 11.67 0.0097
2022-08-10 2022-06-30 13F VERTEX PHARMACEUTICALS STOCK 92532F100 2,554 724 39.56 720 50.63 0.0080
2022-04-25 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,830 -504 -21.59 478 -7.18 0.0074
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS Stock 92532F100 2,334 821 54.26 515 87.96 0.0078
2021-10-25 2021-09-30 13F Vertex Pharmaceutica Stock 92532F100 1,513 43 2.93 274 -7.43 0.0060
2021-08-11 2021-06-30 13F VERTEX PHARMACEUTICALS Stock 92532F100 1,470 107 7.85 296 1.02 0.0065
2021-08-11 2021-03-31 13F/A-1 VERTEX PHARMACEUTICALS Stock 92532F100 1,363 82 6.40 293 -3.30 0.0070
2021-05-12 2021-03-31 13F VERTEX PHARMACEUTICALS Stock 92532F100 1,393 112 299 0.0089
2021-02-11 2020-12-31 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 1,281 193 17.74 303 2.36 0.0097
2020-11-12 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,088 -88 -7.48 296 -13.20 0.0122
2020-08-17 2020-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,176 14 1.20 341 23.55 0.0188
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,176 14 341 18,806.9655
2020-05-14 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,162 100 9.42 276 18.45 0.0174
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,062 -651 -38.00 233 -19.66 0.0119
2019-10-30 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,713 105 6.53 290 -1.69 0.0170
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,608 -326 -16.86 295 -17.13 0.0186
2019-05-14 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,934 -438 -18.47 356 -9.41 0.0240
2019-02-06 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,372 -138 -5.50 393 -18.80 0.0263
2018-11-15 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,510 1,028 69.37 484 92.06 0.0335
2018-08-15 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,482 1,482 252 0.0186
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.